MIPI Calculator
Calculate the MIPI (Mantle Cell Lymphoma International Prognostic Index) score for mantle cell lymphoma risk stratification. Enter age, ECOG status, LDH, and WBC for prognosis assessment with charts.
About This Calculator
The MIPI Calculator (Mantle Cell Lymphoma International Prognostic Index) is a validated clinical tool for risk stratification of patients newly diagnosed with mantle cell lymphoma (MCL). Developed by Hester and colleagues in 2008 based on a study of 455 patients with advanced-stage MCL, the MIPI uses four independent prognostic factors — age, ECOG performance status, serum lactate dehydrogenase (LDH) level normalized to the upper limit of normal (ULN), and white blood cell (WBC) count — to classify patients into three risk groups with significantly different survival outcomes.
The MIPI score is calculated using the formula: MIPI = 0.03535 × age + 0.6978 (if ECOG > 1) + 1.367 × log₁₀(LDH/ULN) + 0.9393 × log₁₀(WBC × 1000). The resulting score stratifies patients: Low risk (<5.7, median survival not reached with >60% 5-year survival), Intermediate risk (5.7–6.2, median survival ~51 months), and High risk (≥6.2, median survival ~29 months).
Regional Notes
India: The MIPI is used in major hematology centers across India for MCL risk stratification. Ki-67 immunohistochemistry (MIPIb) is routinely added in Indian tertiary care hospitals. Serum LDH ULN varies between laboratories (typically 160–250 U/L depending on the assay). WBC count reference ranges are the same as international standards (4.3–10.8 ×1000/µL).
United States: The NCCN guidelines recommend MIPI for initial risk assessment of all newly diagnosed MCL patients. The MIPIb (incorporating Ki-67) is increasingly used alongside the basic MIPI. Modern treatments including BTK inhibitors and CAR-T therapy have improved outcomes across all risk groups.
United Kingdom: The British Committee for Standards in Haematology and NICE guidelines endorse MIPI for MCL risk stratification. The MIPI is used in NHS hematology centers to guide treatment intensity decisions, from rituximab-bendamustine for low-risk patients to more aggressive protocols for high-risk cases.
Important Note
The MIPI is a statistical tool based on group data. It cannot predict individual outcomes and should not replace a comprehensive clinical assessment by a hematologist-oncologist. The introduction of targeted therapies (BTK inhibitors, venetoclax, CAR-T cells) has improved outcomes across all risk groups since the original MIPI was validated.
Frequently Asked Questions
What is MIPI in mantle cell lymphoma?
MIPI stands for Mantle Cell Lymphoma International Prognostic Index, a validated scoring system that uses four independent risk factors — age, ECOG performance status, serum LDH level (relative to the upper limit of normal), and white blood cell count — to stratify newly diagnosed mantle cell lymphoma patients into low, intermediate, and high-risk groups with significantly different survival outcomes.
What are the MIPI risk groups and their survival rates?
The MIPI divides patients into three risk groups: Low risk (MIPI score < 5.7) with a five-year overall survival exceeding 60% and median survival not yet reached, Intermediate risk (MIPI 5.7 to 6.2) with a median overall survival of approximately 51 months, and High risk (MIPI ≥ 6.2) with a median overall survival of approximately 29 months based on the original Hoster et al. study of 455 advanced-stage MCL patients.
What is the ECOG performance status and how is it scored?
The ECOG (Eastern Cooperative Oncology Group) Performance Status is a scale from 0 to 4 that measures a patient's level of functioning. Grade 0 means fully active with no restrictions, Grade 1 allows light work despite symptoms, Grade 2 indicates the patient is ambulatory and capable of self-care but unable to work, Grade 3 means limited self-care with more than 50% of the day in bed, and Grade 4 indicates complete disability confined to bed or chair.
What laboratory values are needed to calculate the MIPI score?
Two laboratory blood test results are required for MIPI calculation: serum lactate dehydrogenase (LDH) level measured in U/L, and the upper limit of normal (ULN) for LDH specific to the local laboratory performing the test (commonly 160 U/L but varies by institution), plus the white blood cell (WBC) count expressed in thousands per microliter (×1000/µL).
How is the MIPI score calculated exactly?
The MIPI score uses the formula: MIPI = 0.03535 × age (years) + 0.6978 (if ECOG greater than 1) + 1.367 × log₁₀(LDH/ULN) + 0.9393 × log₁₀(WBC × 1000). The ECOG adjustment term of 0.6978 is only added when the ECOG performance status is 2, 3, or 4. The resulting score is then compared against the published thresholds of 5.7 and 6.2 to determine the risk category.
Can the MIPI score predict individual patient outcomes?
The MIPI score is a statistical tool based on group-level data from 455 patients and describes median survival probabilities for each risk category. It cannot predict individual outcomes — a low-risk patient may still have aggressive disease, and high-risk patients can achieve long-term remission with modern treatments such as Bruton tyrosine kinase inhibitors, CAR-T cell therapy, or stem cell transplantation.
Is the MIPI used in clinical practice outside the United States?
Yes, the MIPI is widely adopted in hematology-oncology practice globally, including in India, the United Kingdom, and across Europe. It is endorsed by the European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) for risk stratification of newly diagnosed mantle cell lymphoma. The biological MIPI (MIPIb) which adds Ki-67 proliferation index is also commonly used in specialized centers.
How do modern targeted therapies affect MIPI-based prognosis?
The original MIPI was validated in patients treated with immunochemotherapy. Modern targeted therapies — including BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib), venetoclax, and CAR-T cell therapy — have significantly improved outcomes across all risk groups. The MIPI remains useful for initial risk stratification but should be interpreted alongside newer molecular markers and the Ki-67 proliferation index for treatment planning.